Asset profile
Zoledronic acid
Small molecule
Evidence outlook · registrational program
NCT00127205 · Breast Cancer
This registrational program is split: one trial met its primary endpoint and another missed. The grade and rationale below record what each trial was designed to show and what it found.
NCT00127205: This was a large randomized, open-label, three-arm active-controlled trial with 2,231 participants in the zoledronic acid arm, 2,235 in the clodronate arm, and 1,552 in the ibandronate arm. Its hard clinical primary endpoint, disease-free survival, was not significantly different between treatments, so the findings provide useful but inconclusive evidence for a benefit of zoledronic acid.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zoledronic Acid: this drug | Phase 3 | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(23 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (10)
January 2027 (1)
What to watch
February 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (6)
January 2028 (2)
February 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
2030 (3)
February 2030 (1)
What to watch
August 2030 (1)
What to watch
October 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.